칼시토닌 고분자 미립자 투여에 따른 골다공증 유발 쥐의 골밀도 변화

최정원(Jeong won Choi),정제순(Je soon Jung),이상건(Sang Gun Lee),백두진(Doo Jin Paik),박일규(Il Kyu Park),박용구(Yong Goo Park),김미정(Mi Jung Kim) 대한임상노인의학회 2003 대한임상노인의학회지 Vol.4 No.4

Objective: To evaluate bone protective effects of salmon calcitonin microspheres against cancellous bone loss in ovariectomized rats. Method: Thirty five osteoporosis-induced Sprague-Dawley rats were randomly divided into five groups (high dose calcitonin group (112 U/kg), low dose calcitonin group (56 U/kg), free calcitonin group, only ovariectomy group, control group). Ovariectomized rats were injected s.c. with salmon calcitonin microspheres(l12 U/kg or 56 U/kg) weekly, and free salmon calcitonin on alternate days. control rats and the remaining ovariectomized rats were injected s.c. on alternate days with saline vehicle. The effects and side effects in each group were assessed by the bone mineral density and bone histomorphomeσy. Results: 1. At four months after the ovariectomy, the bone mineral densities in high dose calcitonin group were 0.1640±0.0156 grn/㎠, the bone mineral densities in low dose calcitonin group were 0.1600±0.0114 gm/㎠, the bone mineral densities in calcitonin group were 0.1531±0.0168 gm/㎠, the bone mineral densities in ovariectomy group were 0.1404±0.0070 gm/㎠, the bone mineral densities in control group were 0.1896±0.0163 gm/㎠. The bone mineral densities of the femur in ovrariectomy groups compared with control group were decreased with time. The difference of the bone mineral densities between high and low dose calcitonin group and ovariectomy groups was significant (p<0.05). 2. We found that the bone trabeculi in bone histomophometry were more maintained in high dose calcitonin group compared with ovariectomy group. Conclusion: 1. Bone mineral densities of salmon calcitonin microsphere injected rats was higher than only ovariectomized rats in femur. 2. Bone mineral densities of salmon calcitonin microsphere injected rats had no significant differences than only ovariectomized rats in L5 vertebra. 3. In histologic examination, salmon calcitonin microsphere and free salmon calcitonin injected rats showed more prominent bony trabeculae than ovariectomized rats.

뇌실내 Calcitonin 투여로 인한 위산분비 억제에 대한 뇌내 신경전달체의 역할

장우익(Woo Ick Jang),이동기(Dong Ki Lee),권상옥(Sang Ok Kwon),고창만(Chang Mann Ko),현재헌(Jae Hun Hyun),김상태(Sang Tae Kim),이상인(Sang In Lee),최흥재(Heung Jai Choi),김경환(Kyung Hwan Kim) 대한내과학회 1991 대한내과학회지 Vol.40 No.5

Peptides that are common to the brain and gut are thought to play intermediary roles as neurotransmitters or neuromodulators in the regulation of gut function. Calcitonin is a polypeptide hormone of 32 amino acid residues. Recently, much evidence has been accumulated to suggest that calcitonin may inhibit gastric acid secretion by a central action, but the neurohumoral pathways mediating the antisecretory effects of calcitonin in rats are not well elucidated. In the present study, using a gastric perfusion technique, the effects of ICV administration of calcitonin on gastric acid secretion stimulated by baclofen were investigated in rats. We also investigated whether the serotonergic system is involved in calcitonin's effect of gastric acid secretion. The results obtained were as follows: 1) ICV administration of baclofen stimulated gastric acid secretion in a dose-dependent manner. Central administration of baclofen was approximately 200-400 times more sensitive than subcutaneous administration. 2) Baclofen-induced gastric acid secretion was partially suppressed by bilateral vagotomy. 3) Gastric acid secretion stimulated by baclofen was markedly suppressed by ICV administration of calcitonin. 4) Depletion of brain serotonin with the neurotoxin 5, 7-dihydroxytryptamine did not influence calcitonin-induced gestric acid suppression. In this study it was demonstrated that centrally- administered calcitonin suppresses baclofen-induced gastric acid secretion. Also. it is suggested that the serotonergic system is not involved in calcitonin-induced gastric acid suppression.

Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults

송의연,전민지,류혜진,배성진,김태용,김원배,송영기,김홍규,김원구 대한내분비학회 2021 Endocrinology and metabolism Vol.36 No.2

Background: Serum calcitonin measurement contains various clinical and methodological aspects. Its reference level is wide andunclear despite sensitive calcitonin kits are available. This study aimed to identify the specific reference range in the healthy Koreanadults. Methods: Subjects were ≥20 years with available calcitonin (measured by a two-site immunoradiometric assay) data by a routinehealth checkup. Three groups were defined as all eligible subjects (group 1, n=10,566); subjects without self or family history ofthyroid disease (group 2, n=5,152); and subjects without chronic kidney disease, autoimmune thyroid disease, medication of protonpump inhibitor/H2 blocker/steroid, or other malignancies (group 3, n=4,638). Results: This study included 6,341 male and 4,225 female subjects. Males had higher mean calcitonin than females (2.3 pg/mL vs. 1.9 pg/mL, P<0.001) in group 1. This gender difference remained similar in groups 2 and 3. Calcitonin according to age or bodymass index was not significant in both genders. Higher calcitonin in smoking than nonsmoking men was observed but not in women. Sixty-nine subjects had calcitonin higher than the upper reference limit (10 pg/mL) and 64 of them had factors associated with hypercalcitoninemia besides medullary thyroid cancer. Our study suggests the reference intervals for men who were non, ex-, currentsmokers, and women (irrespective of smoking status) as <5.7, <7.1, <7.9, and <3.6 pg/mL, respectively. Conclusion: Specific calcitonin reference range should be provided considering for sex and smoking status. Taking account for several factors known to induce hypercalcitoninemia can help interpret the gray zone of moderately elevated calcitonin.

The Effects of Blood Somatomedin-C,Calcitonin and Osteocalcin Level on Weight Lift Athletes` BMD

Jeong, Ill Gyu,Yoon, Jin Hwan,Lee, Hee Hyuk 한국운동과학회 2002 운동과학 Vol.11 No.2

정일규, 윤진환, 이회혁. 혈중 Somatomedin-C, Calcitonin, Osteocalcin 수준이 중량부하 운동선수의 골밀도에 미치는 영향. 운동과학, 제11권 제2호, 431-440, 2002. 본 연구의 목적은 Somatomedin-C(IGF-1: 이후 IGF-1으로 표기), Osteocalcin 그리고 Calcitonin과 같은 골대사 지표가 골밀도와 갖는 관련성을 조사하는데 있다. 본 연구의 대상자는 10명의 역도선수(평균연령 18.5土5세)와 같은 연령층의 일반 청소년 10명을 대상으로 하였다. 모든 대상자의 요추부 골밀도를 이중 에너지흡수계측법(DEXA)을 이용하여 측정하였으며, 얻어진 골밀도와의 관련성을 찾기 위해서 혈중 골밀도 대사 지표로서 IGF-1, Osteocalcin, Calcitonin을 측정하였다. 중량부하운동 선수집단과 일반인 집단간에 유의한 요추 골밀도의 차이가 있는 것으로 나타났으며(p<.002), 혈중 IGF-1수준도 중량부하 운동선수집단이 현저히 높은 수준을 보였다(p<.05). 또한 BMD와 IGF-1사이에 유의한 상관관계가 있는 것으로 나타났다. 그 밖에 두 집단간 혈중 Calcitonin과 Osteocalcin의 수준에는 유의한 차이가 없었으며, 이 호르몬 수준과 골밀도 사이에도 유의한 상관관계가 나타나지 않았다. 이와 같은 결과는 저항성 운동훈련이 인체 특정 부위의 골밀도 증가에 영향을 미치며, 이는 역도선수에게서 발견되는 보다 높은 안정시 IGF-1수준과 관련이 있는 것으로 보인다. Jeong, I.G., Yoon, J.H., Lee, H.H. The Effects of Blood Somatomedin-C, Calcitonin and Osteocalcin Level on Weight Lift Athletes' BMD. Exercise Science, 11(2): 431-440, 2002. The purpose of this study was to investigate the relationship between bone mineral density(BMD) and Insulin-like growth factor-1(IGF-1), Osteocalcin and Calcitonin in adolescent weight lifter and non-athletes. The subjects in this study were 10 adolescent weight lifters and 10 age-matched non athletes. In all subjects, BMD in lumbar spine was measured using dual-energy x-ray absorptiometry and to investigate the possible hormonal relationships underlying the effects on BMD, serum concentrations of IGF-1, Osteocalcin and Calcitonin were measured. As a results, there were significant difference in mean BMD and resting IGF-1 level between two groups. But there was no significant difference in the level of Osteocalcin and Calcitonin between two groups. We also found the significant correlation between BMD and IGF-1 but not among the other variables. These findings suggest that resistance exercise training might increase the regional bone mineral density, which would be affected by the higher IGF-1 level found in weight lifters.

Calcitonin Transport through Skin Using Iontophoresis

( Kyung Min Kim ),( Seaung Youl Oh ) 한국약제학회 2011 Journal of Pharmaceutical Investigation Vol.41 No.1

The objective of this work is to study transdermal delivery of calcitonin using iontophoresis and to evaluate various factors which affect the transdermal transport. We have studied the effect of polarity, current density, drug concentration, penetration enhancers (isopropyl myristate [IPM] and ethanol) and laser treatment on transdermal flux and the results were compared. We also investigated the iontophoretic flux from microemulsions containing calcitonin together with oleic acid (OA) or IPM. In vitro flux study was performed at 33oC, using side-by-side diffusion cell and full thickness hairless mouse skin. Anodal delivery at pH 3.0 was much larger than cathodal and passive delivery, due to the positive charge of calcitonin. Cumulative amount delivered (CUM) by cathodal or passive delivery was close to zero for 10 hours. The pretreatment of skin by neat IPM markedly increased the CUM anodically. CUM increased as the current density, drug concentration or the duration of IPM treatment increased. Microemulsion containing IPM or oleic acid was prepared and the phase diagram was constructed. CUM also increased when IPM was incorporated into a microemulsion. OA microemulsion showed similar enhancing effect to IPM microemulsion. The delivery of calcitonin from 70% (v/v) ethanol aqueous solution showed a large increase in flux. Laser treatment of skin before flux experiment exhibited about 2 fold increase in total calcitonin amount transported for 12 hours, when compared to that delivered by IPM microemulsion. Based on these results, we have evaluated the possibility of delivering enough amount of calcitonin to reach the therapeutic level. The data suggest that it is highly possible to deliver clinically effective amount of calcitonin using iontophoresis patch with small area (<10 cm2).

칼시토닌 분비 췌장 내분비 종양을 동반한 다발내분비샘종양 1형 1예

김홍익 ( Hong Ik Kim ),최준혁 ( Jun Hyeok Choi ),오훈규 ( Hoon Kyu Oh ),배성화 ( Sung Hwa Bae ),류헌모 ( Hun Mo Ryoo ),김성규 ( Seong Gyu Kim ),강선미 ( Sun Mi Kang ) 대한내과학회 2012 대한내과학회지 Vol.83 No.6

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant hereditary disorder characterized by the combined occurrence of tumors of the parathyroid gland, exocrine pancreas, and anterior pituitary gland. Calcitonin-secreting pancreatic endocrine tumors are rare, and calcitonin-secreting pancreatic endocrine tumors with MEN1 have not been reported in Korea. A 46-year-old woman was admitted for a right breast cancer operation. Abnormal blood chemistry findings were hypercalcemia and elevated calcitonin. The patient was diagnosed with a calcitonin-secreting pancreatic endocrine tumor, left thyroid papillary carcinoma, right breast invasive ductal carcinoma, a thymic carcinoid tumor, left adrenal adenoma, uterine myoma, and adenomyosis by computed tomography scan, and with pituitary macroadenoma by brain magnetic resonance imaging. We present this case with a review of the literature, because it is the first reported calcitonin-secreting pancreatic endocrine tumor with MEN 1 in Korea. (Korean J Med 2012;83:817-822)

The Efficacy of Intramuscular Calcitonin Injection in the Management of Lumbar Spinal Stenosis

Alireza Ashraf,Mehdi Khodadadi,Amin Sadraei,Mahshid Naseri,Ali Nasseri 대한척추외과학회 2015 Asian Spine Journal Vol.9 No.1

Study Design: A prospective, cross-sectional, non-randomized study. Purpose: To assess the effectiveness of intramuscular calcitonin injection in the treatment of lumbar spinal stenosis (LSS). Overview of Literature: LSS, manifesting as chronic low back pain and neurogenic claudication, is a chronic condition with an increasing incidence in the elderly population having inadequate effective conservative treatment options. Methods: In this study, 36 patients with LSS who were diagnosed based on the clinical findings and magnetic resonance imaging were included. Patients received 100 IU of calcitonin per week for one month and were evaluated before and after treatment using the Oswestry disability index (ODI) questionnaire and visual analogue scale (VAS). Before treatment, the patients were divided into two subgroups based on their ODI results: patients with mild to moderate low back pain (disability, 0%–40%) and patients with severe or very severe low back pain (disability, 40%–100%). Results: In patients with mild to moderate low back pain, there were no significant changes in the ODI and VAS after calcitonin injection. But in patients with severe or very severe low back pain, pain severity, personal functions, ability to lift and carry objects, time interval between standing and initiation of pain, social life, disability percentage, and VAS were significantly improved after treatment with calcitonin. Conclusions: It seems that an intramuscular injection of low dose of calcitonin may have some beneficial effects on the pain due to LSS, especially in patients who suffer from severe or very severe low back pain.

한국재래산양 갑상샘에 있어서 Calcitonin면역 반응세포의 개체발생

이재현,구세광,이형식,Lee, Jae-hyun,Ku, Sae-kwang,Lee, Hyeung-sik 대한수의학회 1996 大韓獸醫學會誌 Vol.36 No.3

The development of calcitonin, serotonin(5-HT) and bovine chromogranin (BCG)-immunoreactive cells was investigated in the thyroid glands of Korean native goat from fetus to adult, using an immunohistochemical method. Moderate number of calcitonin-immunoreactive cells were present in the thyroid glands from 1 month to 6 months after birth, whereas a few in the adult. They were not present in the thyroid glands of fetus and 1 day after birth. A number of 5-HT- and BCG-immunoreactive cells were present in the thyroid glands of Korean native goat from fetus to adult. They were increased in number with age. BCG-immunoreactive cells were weakly reacted in fetus and 1 day after birth, while these cell were strongly stained from 1 month to adult. These findings suggest that calcitonin-, 5-HT- and BCG-immunoreactive cells were present in the thyroid gland of Korean native goat.

A Calcitonin-Negative Neuroendocrine Tumor Derived from Follicular Lesions of the Thyroid

김가영,박철연,조창호,박준식,정의달,전언주 대한내분비학회 2015 Endocrinology and metabolism Vol.30 No.2

Neuroendocrine lesions of the thyroid are rare. The most common types are medullary thyroid carcinomas (MTCs) and C-cell hyperplasia. MTCs originate from thyroid parafollicular cells that secrete calcitonin which serves as a serum marker of MTCs. Here, the rare case of a calcitonin-negative neuroendocrine tumor (NET) derived from follicular lesions of the thyroid is described. A 34-year-old man presented at our hospital for the surgical management of an incidental thyroid nodule that was observed on an ultrasound sonography (USG) of the neck. Initially, USG-guided aspiration cytology was performed, and a MTC was suspected. The expressions of thyroglobulin and thyroid transcription factor-1, which are thyroid follicular cell markers, and synaptophysin and chromogranin A, which are neuroendocrine markers, was confirmed following surgical pathology. However, the staining of calcitonin, a marker of MTCs, was not observed. A nonmedullary NET of the thyroid is uncommon, and the distinction between calcitonin-negative NETs and MTCs of the thyroid may be important due to differences in their clinical courses and management.

성인 고형암 환자의 고칼슘혈증 치료현황과 치료효과 분석

신다은,박설희,김성환,서성연,조윤희,조윤숙,임석아,이주연 한국임상약학회 2019 한국임상약학회지 Vol.29 No.3

Background: Hypercalcemia is an important metabolic emergency condition in cancer patients. Bisphosphonate is the treatment of choice for hypercalcemia, whereas calcitonin and hydration with furosemide are recommended for acute supportive therapy. However, data regarding real-world treatment patterns and outcomes of pharmacological treatments are limited. Therefore, we aimed to investigate the treatment patterns and clinical outcomes of hypercalcemia treatment in solid tumor patients. Methods: Electronic medical records of 123 adults with solid cancers and albumin-corrected calcium levels >10.5 mg/dL or ionized calcium levels >1.35 mmol/L were reviewed. We retrospectively analyzed the pharmacological treatment and recovery rate according to the severity of hypercalcemia. Results: A total of 177 cases were identified, of which 49 were not treated and 30 were treated with hydration only. In moderate-to-severe cases, 86.5% received pharmacological treatment. Thirty-four cases (19.2%) were treated with bisphosphonate alone and 58 cases (32.8%) were treated with bisphosphonate and calcitonin. In mild hypercalcemia cases, the recovery rate was higher for those receiving hydration only or pharmacological treatment (79.7%) than for those receiving no treatment (61.4%, p = 0.041). Most moderate-to-severe cases were treated with medication and of those treated, 56.3% recovered. The recovery rate was lower in those treated with bisphosphonate alone (38.2%) than in those who underwent calcitonin combination treatment (73.7%, p = 0.001). Conclusions: Bisphosphonate combined with calcitonin was found to be more effective than bisphosphonate alone for the treatment of moderate-to-severe hypercalcemia. Considering the current shortage of calcitonin, further efforts are required to ensure its stable supply.